Sells image-guided surgical robotic systems and single-use handpieces for minimally invasive prostate surgery to hospitals and distribution partners.
10-K for FY2025, filed Feb 26, 2026
Hospitals and other buyers purchase robotic systems and single-use handpieces; service agreements are invoiced annually at the start of each coverage period.
10-K for FY2025, filed Feb 26, 2026Our revenue is primarily generated from sales of our robotic systems and the accompanying single-use disposable handpieces, and we are…View ↗
Currently, in the United States, we primarily sell our products to hospitals, or end customers, and to a lesser extent, distribution…View ↗
The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue…View ↗
$308.1M
10-K for FY2025, filed Feb 26, 2026
$308.1M ↗
Hospitals are the main U.S. buyers; sales are primarily direct, with some sales to distribution partners, outpatient surgery centers and leasing companies. Outside the United States, sales are direct or through distribution partners.
10-K for FY2025, filed Feb 26, 2026
No. It lost $95.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$26.5MView ↗
8-K, filed Aug 4, 2026
The Company reiterates revenue for the full year 2026 to be in the range of $390 million to $410 million, which represents growth of 27% to…View ↗
Growing. Revenue grew 8.9x in 4 years, from $34.5M in FY2021 to $308.1M in FY2025, about 73% a year.
Expanded product lineup
The latest report describes HYDROS alongside AquaBeam; both systems use disposable handpieces to deliver Aquablation therapy.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop…View ↗
We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop…View ↗
Broader U.S. sales channels
The older report described U.S. sales to hospitals; the latest also names distribution partners, outpatient surgery centers and leasing companies.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026In the United States, we sell our products to hospitals. These customers in turn bill various third-party payors, such as commercial payors…View ↗
Currently, in the United States, we primarily sell our products to hospitals, or end customers, and to a lesser extent, distribution…View ↗
Competes with Boston Scientific and Teleflex
10-K for FY2025, filed Feb 26, 2026We consider our primary competition to be resective surgical treatments. These include among others, those manufacturers producing devices…View ↗
Loading...